Table 1.
Patients, treatment, and clinical outcome characteristics
| Parameter | Feature | Number of patients (%) 94 (100%) |
|---|---|---|
|
| ||
| Age, years | Median (range) | 53 (20–81) |
|
| ||
| MS | Premenopausal | 37 (39) |
| Postmenopausal | 57 (61) | |
|
| ||
| FIGO stage | IA | 2 (2) |
| IB | 33 (35) | |
| IIA | 7 (7.5) | |
| IIB | 24 (25.5) | |
| IIIA | 0 (0) | |
| IIIB | 26 (28) | |
| IVA | 1 (1) | |
| IVB | 1 (1) | |
|
| ||
| AJCC stage | T1BN0M0 | 33 (35) |
| T1BN1M0 | 2 (2) | |
| T2N0M0 | 24 (26) | |
| T2N1M0 | 7 (7.5) | |
| T2N0M1 | 0 (0) | |
| T3N0M0 | 18 (19) | |
| T3N1M0 | 7 (7.5) | |
| T3N1M1 | 1 (1) | |
| T4N0M0 | 1 (1) | |
| T4N1M0 | 1 (1) | |
|
| ||
| Histology | Pure adenocarcinoma | 54 (57.5) |
| Papillare | 10 (11) | |
| Adenosquamous | 6 (6) | |
| Mucinous | 11 (12) | |
| Endometrioides | 4 (4) | |
| Clear cell | 7 (7.5) | |
| Small cell | 1 (1) | |
| Villoglandular | 1 (1) | |
|
| ||
| Tumor grade | G1 | 23 (24.5) |
| G2 | 39 (41.5) | |
| G3 | 12 (13) | |
| Gx | 20 (21) | |
|
| ||
| LN | N+ | 18 (19) |
| N− | 68 (72) | |
| ND | 8 (9) | |
|
| ||
| Treatment | Surgery | 7 (7.5) |
| Surgery + BT | 5 (5.3) | |
| Surgery + CCRT + BT | 22 (23.4) | |
| Surgery + EBRT + BT | 13 (13.8) | |
| CCRT | 45 (48) | |
| EBRT | 2 (2) | |
|
| ||
| EBRT | 46 Gy/23 fr | 49 (52) |
| 45 Gy/25 fr | 7 (7) | |
| 45.9 Gy/27 fr | 1 (1) | |
| 50.4 Gy/28 fr | 0 | |
| 50 Gy/25 fr | 7 (7) | |
| Boost delivered to enlarged lymph nodes over 2 cm in short axis 59.4 Gy/27 fr to 60 Gy/27 fr (SIB) | 6 (6) | |
| 64 Gy/23 fr + boost delivered to U&P | 4 (4) | |
|
| ||
| BT HDR BT LDR |
30 Gy/4 fr | 25 (24) |
| 22.5 Gy/3 fr | 7 (7) | |
| 15 Gy/2 fr | 25 (27) | |
| 28 Gy/4 fr | 2 (2) | |
| 45 Gy/2 fr | 7 (7) | |
|
| ||
| BT | LDR | 7 (7) |
| HDR | 59 (63) | |
| RSA | 40 (43) | |
| IT | 17(40) | |
| FA | 22 (50) | |
| T&R | 4 (10) | |
|
| ||
| CHTH (DDP) | 1–3 courses | 5 (11) |
| 4–6 courses | 40 (89) | |
|
| ||
| Recurrence | Yes | 44 (47) |
| No | 50 (53) | |
| Age of recurrence | Median (range) | 54 (26–85) |
|
| ||
| Recurrence AMS |
Premenopausal | 15 (34) |
| Postmenopausal | 29 (65) | |
|
| ||
| AF | I–IIA | 13 (30) |
| IIB–IV | 31 (70) | |
|
| ||
| Death | Yes | 48 (51) |
| No | 46 (49) | |
| Age of death | Median (range) | 54 (26–85) |
|
| ||
| Death AMS | Premenopausal | 17 (35) |
| Postmenopausal | 31 (65) | |
|
| ||
| Death AF | I–IIA | 12 (25) |
| IIB–IV | 36 (75) | |
Abbreviations: AF, according to FIGO; AJCC, American Joint Committee on Cancer; AMS, according to menopausal status; BT, brachytherapy; CCRT, radiochemotherapy; CHTH, chemotherapy; DDP, cisplatin; EBRT, external beam radiation therapy; FA, Fletcher applicator; FIGO, International Federation of Gynecology and Obstetrics; fr, fraction; HDR, high-dose rate; IT, interstitial; LDR, low-dose rate; LN, lymph nodes; MS, menopausal status; ND, no data; RSA, roller-shaped applicator; SIB, simultaneous integrated boost; T&R, tandem and ring; U&P, uterus and parametria.